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Abstract
Objective: Non-Hodgkin’s lymphoma (NHL) of bone is a rare entity. The most common histological subtype is diffuse 
large B cell lymphoma (DLBCL). The major presenting symptoms are soft tissue swelling, bone pain and pathological 
fracture. Treatment options are chemotherapy, radiotherapy, surgery, or a combination of these modalities. 
Materials and Methods: We retrospectively analyzed the 18 patients (11 females, 7 males) with NHL of bone who were 
diagnosed and treated between 1995-2005. The median age was 56.5 years. The median duration of symptoms was 4.5 
months. The bone pain was the first symptom in all patients. Tru-cut biopsy was performed for diagnosis in most of the 
cases. Diagnosis in five patients (27.8%) required open biopsy. 
Results: DLBCL (77.8%) was the most common histological type among all patients. Other histological subtypes were 
anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%). According to 
Ann Arbor staging system, 44.4% of patients were Stage I, 11.1% were Stage II and 44.4% were Stage IV. Bone marrow 
involvement was determined in four patients (22.2%). All patients except one were treated with anthracycline-containing 
regimens and eight patients (44.4%) received rituximab combination with chemotherapy. Radiation therapy was per-
formed as the first-line therapy in 9 (50%) patients. The median follow-up was 37 months (range, 2-124 months). Among 
the 17 patients who achieved complete remission, five (27.8%) relapsed. All patients were still alive. The five-year relapse-
free survival was 73.5%.
Conclusion: The treatment of bone lymphoma can be planned according to the stage and location of the disease. 
Although we had a relatively low number of patients, it could be concluded that whether or not radiation therapy is per-
formed, rituximab in combination with systemic chemotherapy has been proven beneficial on survival.
(Turk J Hematol 2010; 27: 29-33)
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Özet
Amaç: Kemik lenfomalarÕ oldukça nadirdir ve en sÕk görülen histolojik alt tip diffüz büyük B-hücreli (DBBHL) non-Hodgkin 
lenfomadÕr (NHL). Hastalar çoúunlukla kemik ya da yumuýak dokuda ýiýlik, kemik aúrÕsÕ ve patolojik kÕrÕk yakÕnmalarÕ ile 
baývururlar. Tedavi genellikle cerrahi, radyoterapi, kemoterapi veya bunlarÕn kombinasyonu ýeklindedir. 
Yöntem ve Gereçler: Bu çalÕýmada, merkezimizde 1995 ve 2005 yÕllarÕ arasÕnda tanÕ alan 18 primer kemik NHL’lÕ (11 
kadÕn, 7 erkek) hasta retrospektif olarak analiz edilmiýtir. HastalarÕn tanÕ anÕndaki medyan yaýÕ 56.5 (27-78) yÕl olup, medy-
an 4.5 (1-36) aylÕk semptom süresinden sonra kliniúe baývurmuýlardÕr. Tüm hastalarda aúrÕ semptomu birinci sÕrada yer 
almakla birlikte 3 hastada (%16.7) B-semptomlarÕ da saptanmÕýtÕr. TanÕ yöntemi olarak çoúunlukla “tru-cut” biyopsi (%66.7) 
uygulanÕrken, hastalarÕn %27.8’inde açÕk operasyonla tanÕ konulmuýtur. Introduction
Non-Hodgkin’s lymphoma (NHL) of bone is a rare disease, 
accounting for approximately 5% of all NHLs and 3% of all 
primary bone malignancies [1,2]. There is a slight male pre-
dominance and most patients are diagnosed in their fourth or 
fifth decade [3]. Although very rare, bone involvement of NHLs 
has been determined in some cases, and primary bone lym-
phoma has also been seen. The most common symptoms in 
bone involvement are classified as bone pain, soft tissue swell-
ing and pathologic fracture. Long bones are the most com-
monly affected sites [3]. Histologically, diffuse large B cell lym-
phomas (DLBCL) are the most prominent subtype [4-6]. Tru-
cut or open biopsy of affected sites is generally required for the 
diagnosis of bone lymphoma. On full staging evaluation, most 
of the patients have early stage disease (stage IE-IIE) and the 
remaining few have advanced stage [3]. Treatment options 
have been defined as chemotherapy, radiotherapy, surgery, or 
a combination of these modalities. Traditionally, stage I or II 
diseases have been treated with radiotherapy [3]. Combinational 
therapy modalities including CHOP, CHOP-like regimen and 
rituximab added to these modalities have been found to be the 
most effective regimens in the last decade [3,7,8]. 
Herein, we report a retrospective analysis of 18 patients 
who were diagnosed as NHL with bone involvement; all 
patients were diagnosed and followed up between 1995 and 
2005.
Materials and Methods
Between 1995-2005, the records of 18 patients with NHL 
of bone who were diagnosed and treated in our center were 
analyzed retrospectively. All patients had a biopsy-proven 
diagnosis of lymphoma established by experienced hemato-
pathologists. Patients were evaluated according to current 
World Health Organization classification [9]. Information includ-
ing patient age, sex, presenting symptoms, sites of involve-
ment, presence of B symptoms, type of diagnostic procedure, 
histological subtype, presence of bone marrow involvement, 
stage of the disease, treatment strategies, response rate, 
relapse pattern, and survival time were ascertained from the 
hospital records. Pretreatment staging evaluations included 
medical history, physical examination, laboratory investigation 
of complete blood count and lactate dehydrogenase (LDH) 
level, computed tomography (CT) scan of the neck, thorax and 
abdomen, and staging bone marrow (BM) biopsy. The clinical 
stage of the disease was designated by using the Ann Arbor 
classification system. Patients with lymph node involvement 
outside the affected site and all patients with other extranodal 
involvement such as lung, liver, etc. were excluded from the 
study. B-symptoms were defined as recurrent fever of more 
than 38°C, night sweats and an unexplained weight loss of 
more than 10% of actual body weight within 6 months prior to 
diagnosis. 
Complete remission (CR) was defined as absence of dis-
ease signs and symptoms one month after the completion of 
treatment. Relapse was defined as the appearance of a new 
lesion in a patient in CR. Overall survival (OS) was calculated 
from the time of diagnosis to the time of death or last follow-up. 
Relapse-free survival (RFS) was measured from the time of 
diagnosis to the time of treatment failure, relapse/progression 
or death from lymphoma. Informed consent was obtained from 
all patients.
Statistical Analysis
All descriptive and survival analyses were performed using 
the SPSS software for Windows. Survival curves (OS and RFS) 
were calculated using Kaplan-Meier method.
Results
The median age of the 18 patients was 56.5 years (range, 
27-78 years). Male/female ratio was 7/11. The median duration 
of symptoms was 4.5 months (range, 1-36 months). The 
median follow-up was 37 months (range, 2-124 months). Bone 
pain was the first symptom in all patients. Long bones were 
involved in 6 patients (34%). Three patients (16.7%) had B 
symptoms at initial presentation. Elevation in serum LDH was 
detected in 5 (27%) patients. The most common diagnostic 
procedure applied during the first application was tru-cut 
biopsy (12 patients, 66.7%). Open biopsy had to be performed 
in 5 patients (27.8%) and 1 patient was diagnosed with lymph 
node biopsy. DLBCL (14 patients, 77.8%) was the most com-
mon histological type of lymphoma among all patients. Others 
were diagnosed as anaplastic large cell lymphoma (2 patients, 
11.1%), Burkitt-like lymphoma (1 patient, 5.6%) and marginal 
Bulgular: DBBHL % 77.8 (14 hasta) oranÕnda en sÕk görülen histolojik alt tip olup, %11.1’i anaplastik büyük hücreli len-
foma, %5.6’Õ Burkitt-benzeri, %5.6’Õ marjinal zon lenfoma olarak belirlenmiýtir. Ann Arbor klinik evreleme sistemine göre 
hastalarÕn %44.4’ü Evre-I, %11,1’i Evre-II, %44.4’ü Evre-IV olarak deúerlendirilmiý, kemik iliúi tutulumu %22.2 hastada 
saptanmÕýtÕr. Bir hasta dÕýÕnda tümüne CHOP veya benzeri antrasiklin içeren kemoterapi protokolleri uygulanmÕý, 8 has-
tada (%44.4) Rituximab tedaviye eklenmiýtir ve bu hastalarÕn hiçbirinde relaps izlenmemiýtir. %50 hastada radyoterapi 
birinci sÕra tedavisi olarak uygulanmÕýtÕr. Medyan 37 (2-124) aylÕk izlemde, tedavilerini tamamlayan ve tam remisyon 
saúlanan 17 hastanÕn 5’inde (%27.8) relaps geliýmiý olup halen tüm hastalar saúdÕr. 5 yÕllÕk hastalÕksÕz saú kalÕm oranÕ 
%73.5 olarak belirlenmiýtir. 
Sonuç: Kemik lenfomalarÕn tedavisi hastalÕúÕn evresi ve lokalizasyonuna göre planlanmalÕdÕr. Radyoterapi uygulansÕn veya 
uygulanmasÕn, özellikle rituximab ile birlikte sistemik kemoterapi yaýam süresini olumlu yönde etkiler görünmektedir.
(Turk J Hematol 2010; 27: 29-33)
Anahtar kelimeler: Hematolojik hastalÕklar, çocuk, invazif mantar infeksiyonu
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staging system, 8 patients (44.4 %) were Stage I, 2 patients 
(11.1%) were Stage II and 8 patients (44.4%) were Stage IV. 
Bone marrow involvement was determined in 4 patients (22.2%).
Since we did not have an established and documented 
clinical protocol, and since there was an extended period 
between the first and last patient, each patient was treated 
with different approaches, such as only radiotherapy, chemo-
therapy, or a combination of both. All patients except one were 
eventually treated with CHOP or CHOP-like anthracycline-
containing regimens. Eight patients (44.4%) also received 
rituximab with chemotherapy in combination. Radiation thera-
py was the first-line therapy in 9 patients (50%). Only 1 patient 
was treated with radiotherapy alone.
At the time of the latest follow-up, no patient had died and 
1 patient was lost to follow-up. The OS was 100% and the RFS 
was 73.5% at five years (Figure 1). Five (27.8%) of the 17 
patients who achieved CR at the end of the treatment relapsed; 
3 of these relapsed patients showed resistance to salvage 
treatments and were alive with disease. The remaining 2 
patients were treated with high-dose chemotherapy with 
autologous stem cell transplantation and achieved a second 
CR. Patients’ characteristics, treatment modalities and out-
comes are shown in Table 1.
Discussion
Bone lymphoma is an uncommon disease. Therefore, clas-
sification, staging, treatment, and prognosis of bone lympho-
ma are controversial. In our study, we evaluated 18 patients 
with NHL involving the bone, retrospectively. In this series, the 
median age of patients was 56.5 years, and this is similar to 
that in the literature [3,8-14]. Although a slight male preponder-
ance has been reported in some studies [3,8], we found a 
female predominance as reported in other studies [10,11,14].
Previous studies have emphasized a predominance of long 
bone involvement [3]; however, the most recently reported 
study of a large series with 131 patients with primary bone 
lymphoma showed that long bones and flat bones were 
equally affected [15]. Bone pain, soft tissue swelling and patho-
logic fracture are the most common symptoms of the disease, 
and B symptoms are reported as in other lymphomas 
[3,10,12]. Our series also demonstrated an equal involvement 
of long and flat bones, as in the previous huge series.
Diffuse large B cell lymphoma is the most common histo-
logical type reported in many studies [3,5,6,8-18]. We also 
established this data in our study. Gianelli et al. [18] reported a 
study of 28 cases with primary bone lymphomas and 26 cases 
with systemic lymphomas involving the bone. Two main histo-
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Table 1. Patients characteristics, treatment modalities and outcomes 
Patient   Age   Gender   Involved  B  Diagnostic  Histology   Stages  Radiotherapy  Chemotherapy   Response  Relapse  Current
     sites  symptoms  procedure              status
1  37  M  Tibia  No  Tru-cut  DLBCL  I  Yes   R-CT  CR  No   CR
2 40  F  Clavicula  No  Open  biopsy  DLBCL  IV  No  R-CT  CR No  CR
3 63  F  Temporal  No  Tru-cut  DLBCL  IV  Yes    CT  CR No  CR
4 56  F  Femur  Yes  Tru-cut  DLBCL,  IV  Yes    CT  CR No  CR
           ANAPLASTIC
5 49  F  Humerus  No  Tru-cut  DLBCL  IV  No    R-CT  CR No  CR
6 58  F  Ulna No  Tru-cut  BURKûTT-LIKE IV  No  CT  CR  No  CR
7 58  M  Rib No  Tru-cut  DLBCL  I  No  R-CT  CR No  CR
8 67  M  Spine  Yes  LN  biopsy  DLBCL  II  No  R-CT  CR No  CR
9 52  F  Mandibula  No  Open  biopsy  DLBCL  II  No  R-CT  CR No  CR
10  78  F  Palatinum  No  Tru-cut  MARGINAL  I  Yes   No  CR  Yes   Alive with
          ZONE           disease
11  55  F  Iliac  Yes  Tru-cut  DLBCL  IV  No  CT  CR  Yes   Alive with 
                     sites
12  37  M  Spine  No  Open biopsy  DLBCL  IV  Yes  CT  CR  Yes   Alive with
                     disease
13 69  M  Femur No Tru-cut  DLBCL  I  Yes  CT  LFU  - LFU
14 58  M  Ethmoid  No Tru-cut  DLBCL  I  No  CT  CR  No  CR
15  63  F  Pelvis  No  Open biopsy  DLBCL  IV   No   CT  CR  Yes  CR
16 33  F  Sternum  No Tru-cut  ALCL I  Yes  CT  CR  Yes    CR
17 27  M  Acromion  No  Open  biopsy  DLCBL  I  Yes  R-CT  CR  No  CR
18  57  F  Femur  No  Tru-cut  DLCBL  I  Yes   R-CT  CR  No   CR
M: Male, F: Female, DLBCL: Diffuse large B cell lymphoma, R: Rituximab, CT: Chemotherapy, ALCL: Anaplastic large cell lymphoma, CR: Complete response, LFU: Lost to follow-uplogical types were established: DLBCL and CD30 (+) anaplas-
tic large cell lymphomas. A retrospective study with a large 
series by Ramadan et al. [15] showed that the most common 
diagnosis was DLBCL, determined in 79% of all patients.
Traditionally, treatment choice of localized stages IE and 
IIE, according to the Ann Arbor classification, was radiation 
therapy alone [3]. Recently, combined therapy with chemo-
therapy was also recommended for localized stages of disease 
[6,19]. In our series, all patients except one were treated with 
anthracycline-containing regimens. Radiation therapy were 
applied to nine (50%) patients. At the end of the treatment, we 
observed a complete response in 17 patients; one patient was 
lost to follow-up. The median follow-up was 37 months. 
Relapses were observed in only five patients during follow-up. 
The five-year RFS was 73.5% . Charousset et al. [13] reported 
a retrospective analysis of 22 patients with primary bone lym-
phoma. Twelve patients were treated with chemotherapy alone 
and eight patients with combined therapy. The mean five-year 
Kaplan-Meier survival was 83.3% for the chemotherapy group 
and 82.5% for the combined therapy group, and the mean 
follow-up was 48 months. They found no significant OS differ-
ence between the chemotherapy and combined therapy 
groups.
Recently, there has been a trend toward better survival with 
combined therapy with chemotherapy and radiotherapy. There 
have been studies demonstrating an improvement in survival in 
patients with primary bone lymphoma with the combined treat-
ment [8,14,16,17].
Most recently, Ramadan et al. [15] retrospectively studied 
131 patients with primary bone lymphoma and compared che-
motherapy alone and combined modality with radiation. In that 
study, patients with advanced-stage disease who received 
chemotherapy plus radiotherapy actually had a poorer out-
come compared with chemotherapy alone (10-year OSs were 
25% and 56% , respectively). Their results did not support the 
routine use of irradiation in the treatment of primary bone lym-
phoma. They also revealed that the addition of rituximab to 
chemotherapy improved the outcome. They showed that 
three-year progression-free survival for patients who received 
rituximab-CHOP chemotherapy was 88% compared with 52% 
for those who received standard CHOP chemotherapy without 
rituximab (p=0.025).
In our series, eight patients (44.4%) also received rituximab 
in addition to chemotherapy; all of them achieved CR and none 
relapsed. There are other studies in the literature showing the 
effectiveness of rituximab in improving the outcome in patients 
with bone lymphoma, especially in patients who had resistant 
disease [20,21]. Recently, Beal et al. [12] published a study 
including 82 patients with bone lymphoma. They compared 
CHOP and CHOP plus rituximab, and demonstrated that ritux-
imab was likely to be effective not only in chemoresistant 
patients but also in untreated patients.
In conclusion, anthracycline-containing chemotherapy regi-
mens, especially with rituximab and radiotherapy, seem to be 
effective in the treatment of NHL of bone. However, random-
ized, controlled large prospective clinical trials will determine 
the role of radiotherapy and combined therapy.
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